Cancer Genetics, Inc. (CGI) is a leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology.
Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.
CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our clinical reference laboratory is both CLIA-certified and CAP-accredited. In addition we have approvals and accreditations from the states of Florida, Maryland, New York, California, and New Jersey. Our clinical trial support services and global facilities help biotech and biopharma companies deliver more personalized treatments to market.
CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership. Our dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new tests. CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.
With locations in the US, India, and China, we are helping to empower personalized cancer treatment around the globe.
Acute myeloid leukemia (AML) is a bone marrow cancer that progresses rapidly creating a therapeutically challenging disease to accurately diagnose and prognosticate. Bone marrow analysis with cytogenetics is used to predict remission rates, relapse risks, and overall survival outcomes. Molecular markers such as mutations and small insertions/deletions exhibit clinical relevance by helping to refine prognostic groups. Common molecular markers include CEBPA, FLT3-ITD, cKIT, and NPM1. Interpretation of the clinical relevance of mutations in AML must be considered in the context of cytogenetic-risk categories but also with respect to other mutations.
By offering the most comprehensive testing panel available, CGI’s AML Complete™ Program can help in determining the best personalized course of action for the patient.
Karyotyping enables genome-wide detection of aberrations at low resolution that have a diagnostic and prognostic significance.
Cancer Genetics, Inc. has not received any reviews.
Cancer Genetics, Inc. has not received any endorsements.